![Eric Hardter, Ph.D.](https://ds982gbwnvyso.cloudfront.net/Pictures/80x80/P/Pictures%2Fweb%2Fx%2Fx%2Ft%2Ferichardterboyds_184219.jpg)
Eric Hardter, Ph.D.
Eric Hardter, Ph.D., Associate Director, Regulatory Affairs at Boyds Consultants
- Commentary
Cell and gene therapy rare disease drug development in the US – general principles, challenges and a landscape of mutual regulatory concession
Cell and gene therapy rare disease drug development in the US – general principles, challenges and a landscape of mutual regulatory concession